Vitruvias Recalls Superpotent Thyroid Tablets Nationwide
Vitruvias Therapeutics is voluntarily recalling 1,955 bottles of Thyroid Tablets due to superpotency. The FDA classifies this as a Class I recall.
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 5/5 (Critical).
Highest-severity recall. The hazard can cause serious injury or death. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The FDA has classified this recall as Class I, which is the highest severity level for drug recalls indicating a reasonable probability that use of the product will cause serious adverse health consequences or death.
Plain-English summary
Vitruvias Therapeutics is voluntarily recalling 1,955 bottles of Thyroid Tablets, USP, 1/2 Grain (30 mg). The affected product is identified by Lot # 504950 and has an expiration date of 09/30/2026. The recall was initiated on August 21, 2026, and the product was distributed nationwide in the United States.
The FDA has classified this recall as Class I, the most serious classification, because the product is a superpotent drug. Superpotency means the tablets contain more active ingredients than labeled, which can lead to serious adverse health consequences if taken by patients. The recall was initiated by the firm and is currently ongoing.
Patients who have been prescribed this specific lot of Thyroid Tablets should stop using the product and contact their healthcare provider for further instructions. The recall was reported to the FDA on September 23, 2026.
The recalled product
- Product
- THYROID (THYROID)
- Brand
- THYROID
- Manufacturer
- VITRUVIAS THERAPEUTICS INC
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 1,955
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 504950
- Exp Date: 09/30/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same hazard · superpotency
See all →- HighAripiprazole 10 mg tablets recalled after testing superpotent in one lot
FDA (Drugs) · 2025-09-24
- ModerateHYDROmorphone Hydrochloride 50 mg Cassettes Recalled for Superpotency
FDA (Drugs) · 2025-04-30
- HighLevothyroxine Sodium Tablets Recalled Nationwide for Potency Variance
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Content
FDA (Drugs) · 2024-12-18
- ModerateTriamcinolone Acetonide Cream USP Recalled for Out-of-Specification Potency Variance
FDA (Drugs) · 2024-11-27
Similar recalls
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- SevereLevothyroxine Sodium Tablets Recalled for Subpotency
FDA (Drugs) · 2026-07-29
- CriticalAcella Recalls NP Thyroid 15 Tablets Due to Superpotent Drug Risk
FDA (Drugs) · 2020-06-10
- HighLevothyroxine Sodium Tablets recalled nationwide for potency failures
FDA (Drugs) · 2024-12-18
- CriticalRLC Labs Recalls Subpotent Nature Throid Thyroid Medication
FDA (Drugs) · 2020-09-23
- HighLevothyroxine sodium tablets recalled for potency failures nationwide
FDA (Drugs) · 2024-12-18